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Oral folic acid above certain threshold doses results in unmetabolised folic acid in serum. This raises a number of public health safety issues, principally the
potential to mask pernicious anaemia; more recently the theoretical potential for high-dose folic acid to promote cancer has been highlighted. In this paper
we set out to examine the appearance of unmetabolised folic acid both in cord blood from newborn full-term and premature infants and serum from 4-d-old
infants post-formula feeding. Blood was collected from the umbilical cord of eleven infants in the delivery room immediately after birth. A follow-up serum
sample (n 9) was collected 4 d later from infants post-formula feeding. We detected unmetabolised folic acid in cord blood from all infants at birth. In
addition, unmetabolised folic acid was present in serum of seven infants post-formula feeding, six of which had increased from birth. Our results imply
that infants in Ireland, which does not yet have mandatory fortification, could potentially have circulatory unmetabolised folic acid at the time of birth.
We do not know if the presence of folic acid in cord blood will have any adverse consequences. However, if theoretical safety concerns are borne out
by future research, the likelihood is that the longer the exposure the more likely the potential for harm. This would also be the case in infants exposed
to unmetabolised folic acid as a result of formula feeding.
Folic acid: Cord blood: Infants: Ireland: Circulatory unmetabolised folic acid: Infant formula
The term ‘folate’ refers to the entire group of folate vitamin
forms, i.e. the naturally occurring folypolyglutamates found in
food, and folic acid. Folic acid is not found in nature, but is the
synthetic form of the vitamin. Above certain threshold doses,
oral folic acid in the form of synthetic pteroylmonoglutamic
acid saturates the capacity of the intestinal mucosal cells to com-
pletely metabolise it into methylfolate, the natural blood form of
the vitamin. This results in the appearance of unmetabolised, syn-
thetic pteroylmonoglutamate in the circulation. This has been
demonstrated in a young adult population (Sweeney et al. 2003)
and also in the elderly (Kelly et al. 1997). The appearance of
unmetabolised folic acid in circulation raises a number of safety
concerns, the potential to mask pernicious anaemia (Weir &
Scott, 1998) in an elderly population as well as potentially redu-
cing the efficacy of anti-epileptic drugs (Chanarin et al. 1960) are
well-documented concerns. More recently, the theoretical poten-
tial for folic acid to promote cancer has been highlighted (Charles
et al. 2004; Kim, 2004). In countries where pregnant women con-
sume folic acid either actively or passively there is the potential
for unmetabolised folic acid to appear in the fetal circulation
(Lucock et al. 1989; Kelly et al. 1997). It was recently hypoth-
esised that early exposure of the fetus to excess folic acid may
favour the genetic selection of the MTHFR 677T genotype
which is associated with a range of developmental and degenera-
tive conditions including CVD and Alzheimer’s disease (Lucock
& Yates, 2005). Some of these adverse effects may be partially
explained by the anti-metabolic effect of synthetic folic acid.
In most developed countries many infants are fed formula food
containing the synthetic form of the vitamin folic acid, not the
natural 5-methytetrahydrofolate form, as it is readily degraded
during heating (Johan & Magnus, 1980). The practice means
that there is potential for unmetabolised folic acid to appear in
the circulation of infants consuming formula milk. No previous
studies investigating circulatory unmetabolised folic acid have
been carried out in cord blood or in infants. The aim of the pre-
sent study was to investigate levels of unmetabolised folic acid in
cord blood of newborn infants whose mothers had been consum-
ing a normal diet incorporating the standard commercially avail-
able folic acid-fortified foods in Ireland. It is noteworthy that
mandatory fortification of a food staple such as is the case in
the USA had not been implemented in Ireland at the time of
the study and this remains the case today. In addition, we
wanted to look at the effect on circulatory folic acid of feeding
standard commercially available formula milk to 4-d-old infants.
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Methods
Recruitment
Ethical approval was obtained from the Coombe Woman’s Hospi-
tal. Consent forms and parent information leaflets were issued to
mothers who consented to their infant taking part in the study. We
excluded babies who were breast-fed, babies who received sup-
plemental feeding (enteral or parenteral), or infants with any
metabolic or gut disorders, which might have interfered with
the uptake of folic acid. We recruited full-term (n 8) and prema-
ture (n 3) babies. Two were twins born at 32 weeks and one was
premature at 34 weeks.
Blood collection
A 1ml blood sample was collected from the umbilical cord of
each infant in the delivery room immediately after birth to pro-
vide a baseline serum folic acid concentration. A second serum
sample was collected by venepuncture 4 d after the birth date at
the time of the heel-prick test. This was collected approximately
90min after their last formula feed to anticipate the T-max of
folic acid (Kelly et al. 1997). All babies were on 3–4 h formula
feeds. Eleven baseline samples and nine follow-up samples
were collected due to refusal by two parents to allow the
second sampling to take place after originally consenting to the
study.
Dietary questionnaire
A questionnaire was issued to mothers. This included details on
brand name of feed, number of feeds taken between birth and
the second sampling, the amount taken at each feed and particu-
larly the amount taken at the last feed prior to the second
sampling. In addition, the mothers were asked about their use
of folic acid supplements or other multi-vitamins at the time of
cord-blood collection.
Formula feeds administered
Two standard formula feeds were routinely given to the babies in
the present study at the discretion of the medical staff on the
neonatal and post-natal wards. These included Cow and Gate
Premium, which was fortified with folic acid at 10mg/100ml
and SMA Gold Cap, which was fortified at 8mg/100ml (accord-
ing to the nutrition label on these products). The type of feed
consumed by each infant and the amount of folic acid consumed
at their last feed prior to blood sampling are listed in Table 1.
Laboratory analysis
Serum folic acid. All serum samples were assayed for unmeta-
bolised folic acid by HPLC/Sep-Pak/microbiological assay
(Sweeney et al. 2003). This assay separates unmetabolised folic
acid from other folates by HPLC. The separated folic acid
pools were collected and concentrated by solid-phase extraction
using C18 Sep-Pak cartridges. The methanol was then evaporated
from the sample using a speed/Vac pump (Savant Instruments
New York, USA). The dried sample was re-suspended in
sodium ascorbate (0·5%) buffer, plated out in triplicates of
100ml on to a ninety-six-well microtitre plate and a Lactobacillus
casei microbiological assay was performed (Molloy & Scott,
1997). Any triplicate sample not within 5% standard deviation
was repeated. The lower limit of accurately quantifiable detection
of the assay is 0·3125 ng/ml. Concentrations below this level are
detectable but may not be accurately quantifiable.
Formula folic acid. We measured the folic acid content of the
formula feeds to validate that the babies were consuming the folic
acid content stipulated on the formula feed label (Table 1). Total
folate was extracted from the formula milk according to the pro-
cedure of Tamura (1998) and was measured by microbiological
assay (Molloy & Scott, 1997). Formula folic acid levels were
measured by HPLC/Sep-Pak/microbiological assay (Sweeney
et al. 2003).
Statistical analysis
Statistical analysis was based on the Wilcoxon signed rank test
and exact 95% CI for a proportion.
Results
All of our infants (n 11) exhibited unmetabolised folic acid in
cord blood (95% CI 71·5, 100) (Table 2). Unmetabolised folic
acid was also detected in seven out of the nine samples collected
on day 4 of formula feeding. In six of these cases an increase from
baseline occurred. The mean concentration of folic acid at birth
was 0·185mg/l (in the nine babies with a follow-up sample) and
at day 4 post-formula feeding it was 0·468mg/l (2·5 times higher).
We detected higher levels of folic acid in the formula milk than
stated on the product label (Table 1). Cow and Gate Premium was
fortified with folic acid at 10mg/100ml according to the product
Table 1. Folic acid (mg) content of formula feeds consumed according to product label versus our analysis
Subjects Formula feed consumed Folic acid in last feed as per product label (mg) Folic acid in last feed as per our analysis (mg)
Baby 1 (full term) Cow & Gate Premium 8 18·6
Baby 2 (full term) SMA Gold Cap Unknown Unknown
Baby 3 (full term) Cow & Gate Premium 4 9·3
Baby 4 (premature twin 1) SMA Gold Cap 4 6·5
Baby 5 (premature twin 2) SMA Gold Cap 4 6·5
Baby 6 (full term) Cow & Gate Premium 8 18·6
Baby 7 (premature) Cow & Gate Premium 8·5 19·76
Baby 8 (full term) Cow & Gate Premium 5 11·625
Baby 9 (full term) SMA Gold Cap 6 9·743
Baby 10 (full term) SMA Gold Cap 6 9·743
Baby 11 (full term) Cow & Gate Premium Unknown Unknown
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label, however our analysis reported 23·25mg/100ml. SMA
Gold Cap was fortified with folic acid at 8mg/100ml according
to the product label, however our analysis reported 12·99mg/
100ml.
Discussion
All of the infants sampled in the present study exhibited unmeta-
bolised folic acid in their cord blood. This means that infants born
in Ireland under the present conditions (in the absence of manda-
tory fortification) could potentially have unmetabolised folic acid
in cord blood at birth. None of the mothers were consuming folic
acid supplements. The levels of unmetabolised folic acid detected
in the cord blood must therefore have arisen due to recent dietary
intake of folic acid from commercially available fortified foods.
It has been previously documented that many serum constitu-
ents including water-soluble vitamins measured at birth in
maternal and cord blood show higher concentrations in the cord
than in the mother’s blood (Berger, 1998). Unmetabolised folic
acid has never previously been measured in cord blood. The pre-
sence of unmetabolised folic acid in cord blood may hold poten-
tial for harm in terms of adverse effects in the developing fetus,
particularly if large doses are able to pass over the placenta bar-
rier to the fetus. Adverse effects of large doses of folic acid have
previously been demonstrated in a rat model where long-term
high levels of folic acid supplementation resulted in lower birth
weights and shorter vertex–coccyx length (Achon et al. 1999).
It must be remembered, however, that other studies have shown
a protective effect of folic acid supplementation in pregnancy
and in some cancers (Thompson et al. 2001). Additionally long-
term supplementation with folic acid has been demonstrated to
reduce the risk of colorectal cancer (Giovannucci et al. 1998).
The increase in folic acid concentrations after formula feeding
in some of the infants is also noteworthy. The amounts of folic
acid administered in the feeds were in the region of 4–10mg
per feed according to the product label. However, our assays
showed that the levels actually consumed were higher than this.
This may be a problem of overage like that reported in the
USA (Quinlivan & Gregory, 2003). The feeds were administered
every 3–5 h for only 4 d. The levels of folic acid in the serum
increased over this time in some of the infants. If these levels
continue to increase through childhood and adult life there is a
possibility that individuals could be exposed to circulatory folic
acid for their entire lives.
Modern obstetric practitioners advise against the consumption
of pharmacological agents during early fetal development, yet
mothers are advised to consume 400mg supplements for the
first 12 weeks of pregnancy. The beneficial effects of this in
neural tube defect prevention are undisputed. It is not known
whether unmetabolised folic acid is the active ingredient in the
preventative mechanism but it seems unlikely as early observa-
tional studies (Hibbard & Smithells, 1965) illustrated the protec-
tive effect of a high folate status obtained from natural sources
pre-dating fortification or supplementation. Should we expose
the developing fetus to excess folic acid if this excess amount
has no direct benefits? A balance must be struck between prevent-
ing neural tube defects in early pregnancy and megaloblastic
anaemia in later pregnancy with exposure of the fetus to excess
unmetabolised folic acid. Mandatory fortification has not yet
been implemented in Ireland, however, an expert group (Food
Safety Authority of Ireland, 2003) has recently recommended it.
The Committee on Medical Aspects of Food and Nutrition
Policy (2000) report also supports universal folic acid fortification
of flour in the UK. Unmetabolised folic acid concentrations are
likely to be much higher in infants currently exposed to manda-
tory fortification and as well as standard commercially available
fortified foodstuffs as is the case in the USA. This paper illustrates
the need for further debate on threshold doses necessary for max-
imising beneficial effects while minimising any adverse ones.
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